

02-21-02

GP/1626

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. 01-481-D)

RECEIVED

FEB 27 2002

TECH CENTER 1600/2900

7.11.02

In the application of:

Philip Needleman

Serial No. 09/898,772

Filed: July 2, 2001

For: Method of Using Cyclooxygenase-2  
Inhibitors in the Treatment and  
Prevention of Dementia

Before the Examiner: Not Yet Assigned

Group Art Unit: 1626

Asst. Commissioner for Patents  
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application we are transmitting herewith the attached:

1. A. Information Disclosure Statement;  
B. Form 1449 and eighteen (18) cited references;  
C. Postcard.
2. With respect to additional fees:  
A. ☒ No additional fee is required  
B. ☐ Attached is a check in the amount of \$180.00
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail" (EL604657978US) in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231 on this 20<sup>th</sup> day of February, 2002.

By:

Steven J. Sarussi  
Reg. No. 32,784



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. 01-481-D)

RECEIVED  
FEB 27 2002  
TECH CENTER 1600/2900  
#5  
AKO  
7.11.02

In the application of: )  
Philip Needleman )  
Serial No. 09/898,772 )  
Filed: July 2, 2001 )  
For: Method of Using Cyclooxygenase-2 )  
Inhibitors in the Treatment and )  
Prevention of Dementia )

Before the Examiner: Not Yet Assigned

Group Art Unit: 1626

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

This prior art statement is filed under 37 C.F.R. §1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

1. U.S. Patent No. 5,192,753, issued March 9, 1993.
2. U.S. Patent No. 5,760,068, issued June 2, 1998.

3. U.S. Patent No. 6,136,839, issued October 24, 2000.
4. WO 94/13635, published June 23, 1994.
5. WO 95/15316, published June 8, 1995.
6. WO 96/03385, published February 8, 1996.
7. WO 96/09293, published March 28, 1996.
8. WO 96/09304, published March 28, 1996.
9. WO 96/11676, published April 25, 1996.
10. WO 96/38418, published December 5, 1996.
11. WO 96/38442, published December 5, 1996.
12. WO 96/41625, published December 27, 1996.
13. WO 96/41626, published December 27, 1996.
14. WO 96/41645, published December 27, 1996.
15. WO 97/38986, published October 23, 1997.
16. J.R. Vane et al.: "*Cyclo-Oxygenases 1 and 2*", Annu. Rev. Pharmacol. Toxicol., Vol. 38: 1998, pages 97-120.
17. J.Y. Jouzeau et al.: "*Cyclo-Oxygenase Isoenzymes*", Drugs, Vol. 53: No. 4, April 1997, pages 563-582.
18. J. Van Ryn et al.: "*Selective Cyclooxygenase-2 Inhibitors: Pharmacology, Clinical Effects and therapeutic Potential*", Exp. Opin. Invest. Drugs, Vol. 6: No. 5, March 1997, pages 609-614.


In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of

the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

**McDonnell Boehnen  
Hulbert & Berghoff**  
300 South Wacker Drive  
Chicago, Illinois 60606  
312-913-0001

By:

  
Steven J. Sarussi  
Reg. No. 32,784

Dated: February 20, 2002